Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „mode“
Suchtreffer
Begriffe & Kennungen
2019-nCoV-Impfstoff mRNA-1273
Eintrag öffnenAblymico · 4.8 · Gastrointestinal adverse reactions Most episodes of gastrointestinal events were mild to moderate, transient a
Eintrag öffnenAblymico · 4.8 · Patients with mild or moderate renal impairment (creatinine clearance ≥ 30 mL/min) may experience more gastroi
Eintrag öffnenAdempas · 4.5 · 30 PDE5 inhibitors Preclinical studies in animal models showed additive systemic blood pressure lowering effec
Eintrag öffnenAdempas · 4.5 · Concomitant use with CYP3A4 inducers Bosentan, reported to be a moderate inducer of CYP3A4, led to a decrease
Eintrag öffnenAdempas · 4.5 · Concomitant use with CYP3A4 inducers Bosentan, reported to be a moderate inducer of CYP3A4, led to a decrease
Eintrag öffnenAdempas · 4.5 · PDE5 inhibitors Preclinical studies in animal models showed additive systemic blood pressure lowering effect w
Eintrag öffnenAdtralza · 4.8 · The safety of tralokinumab was assessed in patients 12 to 17 years of age (adolescents) with moderate-to-sever
Eintrag öffnenAfinitor · 4.5 · 9 Potent and moderate CYP3A4 inducers Rifampicin AUC ↓63% Avoid the use of concomitant (range 0-80%) potent CY
Eintrag öffnenAfinitor · 4.5 · Everolimus is a substrate of CYP3A4, and also a substrate and moderate inhibitor of PgP. Therefore, absorption
Eintrag öffnenAirway Remodeling
Eintrag öffnenAlimta · 4.5 · In patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min), the concomi
Eintrag öffnenAloxi · 4.8 · In paediatric clinical trials for the prevention of nausea and vomiting induced by moderately or highly emetog
Eintrag öffnenAlunbrig · 4.5 · Moderate CYP3A inducers may decrease the AUC of brigatinib by approximately 50% based on simulations from a ph
Eintrag öffnenAlunbrig · 4.5 · Moderate CYP3A inhibitors (e.g., diltiazem and verapamil) may increase the AUC of brigatinib by approximately
Eintrag öffnenAmgevita · 4.3 · Moderate to severe heart failure (NYHA class III/IV) (see section 4.4).
Eintrag öffnenAmgevita · 4.3 · Moderate to severe heart failure (NYHA class III/IV) (see section 4.4).
Eintrag öffnenAmlodipine / Valsartan Mylan · 4.5 · CYP3A4 inhibitors Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors
Eintrag öffnenAmsparity · 4.3 · Moderate to severe heart failure (NYHA class III/IV) (see section 4.4).
Eintrag öffnenAmsparity · 4.3 · Moderate to severe heart failure (NYHA class III/IV) (see section 4.4).
Eintrag öffnen